NCT01575925 - Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 1, 2012

Primary Completion Date

August 7, 2018

Study Completion Date

August 7, 2018

Conditions

Multiple MyelomaRenal Impairment

Interventions

DRUG

4 mg Oral POM + 40 mg Oral DEX

DRUG

2 mg Oral POM + 40 mg Oral DEX

Trial Locations (9)

Weill Cornell Medical College, New York

Winship Cancer Institute of Emory University, Atlanta

Cleveland Clinic, Cleveland

Ingalls Cancer Research Center, Harvey

MD Anderson Cancer Center, Houston

Colorado Blood Cancer Institute, Denver

Hackensack University Medical Center, Hackensack

Queen Elizabeth II Health Sciences Centre, Halifax

L'Hotel Dieu de Quebec, Québec